1
00:00:15,356 --> 00:00:23,956
Speaker 1: Pushkin. So I'm curious in your own life when you

2
00:00:24,036 --> 00:00:29,196
Speaker 1: first became aware of HIV and AIDS.

3
00:00:29,556 --> 00:00:34,116
Speaker 2: Oh gosh, this is a great question to start interview.

4
00:00:35,396 --> 00:00:41,036
Speaker 2: I am fifty I did one, so I do remember.

5
00:00:41,076 --> 00:00:44,036
Speaker 2: I remember the first news stories as a you know,

6
00:00:44,036 --> 00:00:49,396
Speaker 2: as a child. It's also been a driver of everything

7
00:00:49,396 --> 00:00:51,076
Speaker 2: I've worked on and wanted to work on.

8
00:00:51,716 --> 00:00:56,236
Speaker 1: I am also fifty one, coincidentally, and I you know,

9
00:00:56,476 --> 00:00:59,916
Speaker 1: I vaguely remember the world before HIV and AIDS. I

10
00:00:59,996 --> 00:01:02,436
Speaker 1: also remember, and I'm sure you remember this too, like

11
00:01:02,956 --> 00:01:06,276
Speaker 1: coming of age at a time when if you got AIDS,

12
00:01:06,276 --> 00:01:08,716
Speaker 1: you died, and you could get it from having sex.

13
00:01:09,156 --> 00:01:10,036
Speaker 2: Uh.

14
00:01:10,196 --> 00:01:13,436
Speaker 1: To me, that's the that's the big imprint it left

15
00:01:13,476 --> 00:01:16,876
Speaker 1: on my own you know, narrowly, narcissistically on my own life.

16
00:01:17,116 --> 00:01:20,356
Speaker 2: Yes, so much fear, right, so much, so much death,

17
00:01:21,316 --> 00:01:26,996
Speaker 2: so much destruction, destruction of potential, and so much fear

18
00:01:27,076 --> 00:01:32,316
Speaker 2: and surgainly for a generation to have fear and sex

19
00:01:32,596 --> 00:01:38,356
Speaker 2: so coupled with each other, so intertwined. But it's always

20
00:01:38,396 --> 00:01:41,516
Speaker 2: driven me to to to end HIV is to be

21
00:01:41,596 --> 00:01:44,956
Speaker 2: able for you know, there to be a generation who

22
00:01:45,036 --> 00:01:48,036
Speaker 2: didn't have that cloud of fear in their lives.

23
00:01:54,156 --> 00:01:56,556
Speaker 1: I'm Jacob Goldstein and this is What's Your Problem, the

24
00:01:56,596 --> 00:01:58,596
Speaker 1: show where I talk to people who are trying to

25
00:01:58,676 --> 00:02:03,316
Speaker 1: make technological progress. My guest today is Jared Bayton. He's

26
00:02:03,396 --> 00:02:08,356
Speaker 1: senior vice president in virology Achillead Sciences. Jared's problem is this,

27
00:02:09,156 --> 00:02:11,916
Speaker 1: in a world without a vaccine, how do you prevent

28
00:02:11,996 --> 00:02:17,756
Speaker 1: people from getting HIV. It's been clear for years that

29
00:02:17,836 --> 00:02:21,756
Speaker 1: taking a daily pill dramatically reduces the risk of getting HIV,

30
00:02:22,356 --> 00:02:25,116
Speaker 1: but as you'll hear, the vast majority of people who

31
00:02:25,156 --> 00:02:28,516
Speaker 1: are at high risk for getting HIV just don't take

32
00:02:28,556 --> 00:02:32,236
Speaker 1: a pill every day. Now, Jared and his colleagues are

33
00:02:32,236 --> 00:02:35,516
Speaker 1: working on a new option, a drug called leni kapavir

34
00:02:35,716 --> 00:02:38,716
Speaker 1: that you get as a shot once every six months.

35
00:02:39,036 --> 00:02:42,036
Speaker 1: The drug has not yet been approved to prevent HIV,

36
00:02:42,596 --> 00:02:45,316
Speaker 1: but there have been some really compelling results from a

37
00:02:45,316 --> 00:02:48,556
Speaker 1: couple big clinical trials. There's a lot that's interesting in

38
00:02:48,596 --> 00:02:51,396
Speaker 1: the show today, how medicine only works if it meets

39
00:02:51,396 --> 00:02:54,116
Speaker 1: people where they are, and how what seemed like a

40
00:02:54,156 --> 00:02:57,076
Speaker 1: big problem for Lena kapavir may turn out to be

41
00:02:57,276 --> 00:03:00,476
Speaker 1: the key to its success. But we started with Jared's

42
00:03:00,476 --> 00:03:02,796
Speaker 1: own career, which tracks a lot of the history of

43
00:03:02,996 --> 00:03:06,516
Speaker 1: HIV and AIDS and the emergence of drugs that can

44
00:03:06,596 --> 00:03:10,556
Speaker 1: prevent people from becoming infected. So when do you decide

45
00:03:10,636 --> 00:03:16,836
Speaker 1: to make fighting HIV your career.

46
00:03:17,316 --> 00:03:20,156
Speaker 2: When I went to graduate school and medical school, I

47
00:03:20,156 --> 00:03:22,876
Speaker 2: was when I decided to work on HIV that I

48
00:03:22,956 --> 00:03:26,796
Speaker 2: wanted to do health work that was meaningful to the world.

49
00:03:26,876 --> 00:03:29,716
Speaker 2: That was that it was and it was immediately actionable.

50
00:03:30,356 --> 00:03:33,116
Speaker 2: As a graduate student during medical school, I lived and

51
00:03:33,156 --> 00:03:38,036
Speaker 2: worked on HIV prevention in Kenya. Obviously before there was

52
00:03:39,116 --> 00:03:44,436
Speaker 2: medicine for prevention, and I remember very well, even before

53
00:03:44,516 --> 00:03:46,836
Speaker 2: there was very good testing. I was a strain of

54
00:03:46,836 --> 00:03:50,636
Speaker 2: thought at the time that testing was too scary to

55
00:03:50,676 --> 00:03:52,356
Speaker 2: do because there was nothing to be done.

56
00:03:52,796 --> 00:03:53,236
Speaker 1: Wow.

57
00:03:53,316 --> 00:03:55,916
Speaker 2: I certainly had other doctors say that to me. I

58
00:03:56,156 --> 00:04:01,956
Speaker 2: the hospital that I worked in Kenya, the only testing

59
00:04:02,196 --> 00:04:04,796
Speaker 2: that was done was so people could stop spending money

60
00:04:04,876 --> 00:04:05,836
Speaker 2: on their family members.

61
00:04:05,996 --> 00:04:08,476
Speaker 1: Oh my god, So meaning, oh, don't spend any money

62
00:04:08,516 --> 00:04:11,396
Speaker 1: on them. They have HIV, They're going to die. That's

63
00:04:11,476 --> 00:04:12,836
Speaker 1: why they were doing the tests.

64
00:04:13,036 --> 00:04:15,596
Speaker 2: Yeah, someone in the hospital extraordinarily sick. Let's do an

65
00:04:15,676 --> 00:04:18,596
Speaker 2: HIV test. Okay, you can stop spending money. Jesus and

66
00:04:18,796 --> 00:04:22,236
Speaker 2: then really importantly, I remember when medicines came. I remember

67
00:04:22,276 --> 00:04:25,476
Speaker 2: when medicines came. I remember when I remember very well

68
00:04:25,476 --> 00:04:28,356
Speaker 2: when the coffin makers who would work in the street

69
00:04:28,396 --> 00:04:30,276
Speaker 2: outside the hospital start going out of.

70
00:04:30,236 --> 00:04:34,756
Speaker 3: Business, the coffin makers, the coffin makers, yep, holy yahkah,

71
00:04:36,676 --> 00:04:42,636
Speaker 3: which gosh, the Kenya's prevalence maybe at fifteen percent or

72
00:04:42,676 --> 00:04:44,956
Speaker 3: something like that at some point, and it's.

73
00:04:44,756 --> 00:04:50,356
Speaker 2: Not much lower to be able to see in that

74
00:04:50,396 --> 00:04:53,236
Speaker 2: country and other countries what medicines can do. And that's

75
00:04:53,276 --> 00:04:56,396
Speaker 2: actually that's what drove a lot of signs. I've always done,

76
00:04:56,436 --> 00:05:00,116
Speaker 2: is HIV prevention and then HIV treatment, but making medicines

77
00:05:00,156 --> 00:05:02,556
Speaker 2: that make a difference in people's lives, and like what

78
00:05:02,956 --> 00:05:06,756
Speaker 2: good medicines did for HIV care here in the US

79
00:05:06,796 --> 00:05:09,316
Speaker 2: where I live from, in many parts of Africa where

80
00:05:09,316 --> 00:05:14,876
Speaker 2: I've worked, and how fundamentally transformed, how socially transformative, how

81
00:05:14,956 --> 00:05:20,636
Speaker 2: something risked really destroying in fraction societies, and how good

82
00:05:20,676 --> 00:05:23,716
Speaker 2: science was able to arrest that in averse.

83
00:05:23,756 --> 00:05:28,156
Speaker 1: Then so okay, so that's what's happening, you know, around

84
00:05:28,156 --> 00:05:31,476
Speaker 1: the turn of this century. And then there's this new

85
00:05:31,556 --> 00:05:34,956
Speaker 1: idea that comes along after that right, and that is

86
00:05:35,516 --> 00:05:38,516
Speaker 1: what if we can use these drugs to prevent people

87
00:05:38,556 --> 00:05:42,516
Speaker 1: at high risk from getting HIV in the first place. Right,

88
00:05:42,596 --> 00:05:45,756
Speaker 1: This idea called prep Where does that come from?

89
00:05:46,276 --> 00:05:48,596
Speaker 2: So this idea of prep pre exposure, prople axis, you

90
00:05:48,596 --> 00:05:51,556
Speaker 2: take a medicine. By having that medicine, your bloodstreams, your

91
00:05:51,556 --> 00:05:55,156
Speaker 2: tissues or whatever, you if you expose to the virus,

92
00:05:55,396 --> 00:06:00,676
Speaker 2: it doesn't take hold. Yeah, and the idea of propyle

93
00:06:00,676 --> 00:06:05,036
Speaker 2: axis is not totally novel in infectious diseases. If you've

94
00:06:05,036 --> 00:06:07,436
Speaker 2: ever traveled to a place with malaria, you've probably taken

95
00:06:07,476 --> 00:06:10,996
Speaker 2: a malaria propyle axis that kind of idea, But they

96
00:06:11,116 --> 00:06:15,116
Speaker 2: do prep for HIV was super surprising at the time.

97
00:06:15,236 --> 00:06:15,516
Speaker 1: Huh.

98
00:06:15,556 --> 00:06:18,836
Speaker 2: You have to have a medicine that would work to

99
00:06:18,876 --> 00:06:22,756
Speaker 2: prevent HIV and HIV is very transmissible, so to avert

100
00:06:23,596 --> 00:06:26,916
Speaker 2: infection would be a high bar. And then it has

101
00:06:26,916 --> 00:06:30,516
Speaker 2: to be medicine itself that's very well tolerated, very safe

102
00:06:30,556 --> 00:06:34,476
Speaker 2: because you're it would be given to healthy individuals who

103
00:06:34,516 --> 00:06:38,076
Speaker 2: don't have affection, and the societal medical tolerance for side

104
00:06:38,076 --> 00:06:41,436
Speaker 2: effects for treating HIV, just like treating any really serious

105
00:06:41,556 --> 00:06:44,916
Speaker 2: dead latencies, is different than but for preventing.

106
00:06:44,516 --> 00:06:46,676
Speaker 1: It, sure, it has to be lower risk. Right, if

107
00:06:46,716 --> 00:06:48,756
Speaker 1: you already have HIV and you're going to die, you're

108
00:06:48,796 --> 00:06:51,636
Speaker 1: willing to take a right medicine that has pretty severe

109
00:06:51,676 --> 00:06:55,036
Speaker 1: side effects, whereas if you're healthy, you're not going to

110
00:06:55,116 --> 00:06:58,916
Speaker 1: take some really harsh, risky drug just in case.

111
00:06:59,156 --> 00:07:03,276
Speaker 2: Exactly exactly right and unfortunately for treating HIV. Just for

112
00:07:03,756 --> 00:07:06,516
Speaker 2: your listeners, like the complexity and the side effects of

113
00:07:06,556 --> 00:07:09,476
Speaker 2: the medicines from the late nineties and two thousand have

114
00:07:10,036 --> 00:07:12,836
Speaker 2: changed dramatically in the last couple of decades, and so

115
00:07:12,956 --> 00:07:15,756
Speaker 2: that most people these days actually take a single pill

116
00:07:16,076 --> 00:07:21,396
Speaker 2: once a day, extremely well tolerated, and live what's expected

117
00:07:21,436 --> 00:07:23,036
Speaker 2: to be a full lifespan lived as long as someone

118
00:07:23,036 --> 00:07:26,116
Speaker 2: who doesn't have HIV and are on infections. So just

119
00:07:26,116 --> 00:07:29,276
Speaker 2: so people know what's changing. But in early two thousands,

120
00:07:30,076 --> 00:07:31,436
Speaker 2: medicine still had side effects.

121
00:07:31,436 --> 00:07:33,116
Speaker 1: Were you working on PREP at this time?

122
00:07:33,316 --> 00:07:36,116
Speaker 2: I worked on one of the two trials that formed

123
00:07:36,236 --> 00:07:40,796
Speaker 2: the registrational package of PREP, one in mostly gave men

124
00:07:40,876 --> 00:07:45,796
Speaker 2: and some transgender individuals, and then one in heterosexual individuals,

125
00:07:46,476 --> 00:07:49,596
Speaker 2: women and men, And that was the second one was

126
00:07:49,596 --> 00:07:51,676
Speaker 2: the study that I worked on with collaborators from all

127
00:07:51,716 --> 00:07:54,836
Speaker 2: over the world. And based in Kenyan. You gotta it

128
00:07:54,996 --> 00:07:59,116
Speaker 2: was almost five thousand couples where one person didn't have

129
00:07:59,236 --> 00:08:00,196
Speaker 2: HIV and the other one did.

130
00:08:01,236 --> 00:08:03,556
Speaker 1: So that's a very high risk setting, very.

131
00:08:03,516 --> 00:08:07,036
Speaker 2: Higher setting, and also setting where there was tremendous motivation

132
00:08:07,716 --> 00:08:10,436
Speaker 2: to have a different life experien for the couple it was.

133
00:08:11,036 --> 00:08:13,196
Speaker 2: It was a really remarkable time because there was lots

134
00:08:13,196 --> 00:08:15,156
Speaker 2: of questions where the park would work at all. There

135
00:08:15,156 --> 00:08:16,716
Speaker 2: was not a question where it could be safe enough

136
00:08:17,276 --> 00:08:22,316
Speaker 2: and go to the trials demonstrated both safety and HIV protection.

137
00:08:22,996 --> 00:08:26,036
Speaker 2: Protection that was dependent on people taking it. Like all medicines,

138
00:08:26,076 --> 00:08:28,716
Speaker 2: medicines only work if you take them, and there are

139
00:08:28,716 --> 00:08:31,316
Speaker 2: all kinds of different motivations to take something, predict something

140
00:08:31,356 --> 00:08:33,956
Speaker 2: that's every day, and some people really succeed and some

141
00:08:33,996 --> 00:08:36,636
Speaker 2: people really struggle. As you can access.

142
00:08:36,396 --> 00:08:40,836
Speaker 1: So you are, they're setting up the next turn in

143
00:08:40,916 --> 00:08:43,076
Speaker 1: our story, which is the new drug we are here

144
00:08:43,116 --> 00:08:48,396
Speaker 1: to talk about, right, But let's just do that for

145
00:08:48,436 --> 00:08:52,236
Speaker 1: a minute more, because as you said that the drugs

146
00:08:52,276 --> 00:08:56,396
Speaker 1: people can take to prevent getting HIV have gotten easier

147
00:08:56,436 --> 00:09:00,716
Speaker 1: to take and better tolerated. And you know, if you

148
00:09:00,796 --> 00:09:02,556
Speaker 1: can take one pill a day and you're in a

149
00:09:02,596 --> 00:09:05,316
Speaker 1: high risk setting and that means you have a profoundly

150
00:09:05,316 --> 00:09:09,876
Speaker 1: lower risk of getting HIV. Like, what's the problem? Like

151
00:09:09,916 --> 00:09:12,116
Speaker 1: I feel like, great work, thank you for doing that

152
00:09:12,156 --> 00:09:14,796
Speaker 1: good work, and like it seems like you're there.

153
00:09:18,196 --> 00:09:20,596
Speaker 2: I'm sure there were moments where I thought, it seems

154
00:09:20,596 --> 00:09:23,316
Speaker 2: like we're there. This seems obvious to me as well. Yeah,

155
00:09:23,396 --> 00:09:27,796
Speaker 2: I remember well the first day. Its actually years after

156
00:09:28,156 --> 00:09:32,756
Speaker 2: the first medication for PREP was approved, where it had

157
00:09:32,756 --> 00:09:37,116
Speaker 2: never been something like this hadn't been rolled out in clinics,

158
00:09:37,116 --> 00:09:41,156
Speaker 2: so like people doctors didn't have the conversation pieces to

159
00:09:41,196 --> 00:09:43,836
Speaker 2: talk with this, patients or individuals who wanted PREP didn't

160
00:09:44,196 --> 00:09:48,796
Speaker 2: always have heard about it or didn't have the practice

161
00:09:48,836 --> 00:09:52,876
Speaker 2: and asking for it. And it was slow. It was

162
00:09:52,916 --> 00:09:55,636
Speaker 2: slow going, slow going in this country, slow going around the.

163
00:09:55,596 --> 00:09:59,516
Speaker 1: World, slow going meaning people just didn't take it that much.

164
00:09:59,556 --> 00:10:02,156
Speaker 1: Healthy people didn't want to take a pill every day.

165
00:10:02,316 --> 00:10:04,356
Speaker 2: Yeah, I was like, yes, this is hard, like new

166
00:10:04,476 --> 00:10:07,996
Speaker 2: innovations and health are hard because none of us make

167
00:10:08,076 --> 00:10:11,436
Speaker 2: health decisions, or at least I think most of us.

168
00:10:11,436 --> 00:10:13,436
Speaker 2: Most of us do not make health decisions just because

169
00:10:13,476 --> 00:10:17,116
Speaker 2: someone tells us to or because the science is really excellent.

170
00:10:17,156 --> 00:10:18,876
Speaker 2: We make health decisions because we think it's going to

171
00:10:19,236 --> 00:10:21,316
Speaker 2: be meaningful for us. So whether that's like what we

172
00:10:21,436 --> 00:10:24,196
Speaker 2: eat or going to gym, or like what we buy

173
00:10:24,236 --> 00:10:28,156
Speaker 2: off Instagram or whatever else for our health, Like, we

174
00:10:28,236 --> 00:10:30,716
Speaker 2: make those decisions because we think it's meaningful for us.

175
00:10:30,716 --> 00:10:33,116
Speaker 2: And something like PREP, which can be extorted and meaningful,

176
00:10:33,236 --> 00:10:35,556
Speaker 2: it has to be extortedly meaningful for someone to want

177
00:10:35,596 --> 00:10:38,556
Speaker 2: to make the effort to go to get it and

178
00:10:38,636 --> 00:10:42,116
Speaker 2: to continue it. There are many many people who take

179
00:10:42,116 --> 00:10:44,636
Speaker 2: PREP every single day. It fits into their lives. It

180
00:10:44,636 --> 00:10:47,676
Speaker 2: brings benefit, and it brings meeting and they can make

181
00:10:47,716 --> 00:10:51,156
Speaker 2: it workable within their lives. And then there have been

182
00:10:51,516 --> 00:10:55,396
Speaker 2: many people who have tried and stopped or not tried

183
00:10:55,436 --> 00:10:58,676
Speaker 2: at all. And that's like setting up for my rest

184
00:10:58,716 --> 00:11:04,076
Speaker 2: for our discussion. Just because you have something that works

185
00:11:04,436 --> 00:11:08,516
Speaker 2: for some people, that airing that bottle home or it

186
00:11:08,516 --> 00:11:12,116
Speaker 2: could be found by an aunt, partner or brother or

187
00:11:12,116 --> 00:11:19,556
Speaker 2: whatever is too much, too much disclosure, too much revealing.

188
00:11:20,236 --> 00:11:23,876
Speaker 1: It means you're having sex, probably right, yeah.

189
00:11:23,556 --> 00:11:27,756
Speaker 2: Exactly, Or the complexity of the of taking something every

190
00:11:27,836 --> 00:11:31,396
Speaker 2: day when you've got two jobs and three kids or

191
00:11:31,396 --> 00:11:35,076
Speaker 2: whatever the things are that for something that you don't

192
00:11:35,076 --> 00:11:36,196
Speaker 2: really want to think about every day.

193
00:11:36,716 --> 00:11:40,116
Speaker 1: Yeah, it's a very good qualitative description. Is there a

194
00:11:40,236 --> 00:11:44,356
Speaker 1: quantitative piece like, have you estimated the population that you

195
00:11:44,396 --> 00:11:46,836
Speaker 1: know might be relevant but doesn't want to take a

196
00:11:46,836 --> 00:11:48,036
Speaker 1: pill every day in the first place.

197
00:11:48,316 --> 00:11:52,276
Speaker 2: Yeah, In the US, CC is estimated that maybe about

198
00:11:52,276 --> 00:11:54,956
Speaker 2: a third of the people who would most benefit from

199
00:11:54,996 --> 00:11:57,596
Speaker 2: taking PREP, not even like benefit at all, but like

200
00:11:57,676 --> 00:12:00,996
Speaker 2: most benefit from taking PREP are taking it sort of

201
00:12:00,996 --> 00:12:02,676
Speaker 2: today we are taking it day to day.

202
00:12:02,716 --> 00:12:05,756
Speaker 1: Wait, one third of the people who are at highest

203
00:12:05,876 --> 00:12:08,596
Speaker 1: risk for getting HIV are taking it. So two thirds

204
00:12:08,596 --> 00:12:09,796
Speaker 1: of the people are.

205
00:12:09,556 --> 00:12:12,596
Speaker 2: Not exactly so, a third r a third arth, two

206
00:12:12,596 --> 00:12:13,116
Speaker 2: thirds are not.

207
00:12:13,716 --> 00:12:19,316
Speaker 1: So okay, So there is this idea that PREP is great,

208
00:12:19,356 --> 00:12:21,996
Speaker 1: but most people who could most benefit from it don't

209
00:12:22,036 --> 00:12:26,516
Speaker 1: take it. One thought as well, if instead of having

210
00:12:26,596 --> 00:12:28,996
Speaker 1: to take a pill every day, it was less frequent,

211
00:12:30,156 --> 00:12:32,596
Speaker 1: simple behavioral thing, maybe people would do it more often.

212
00:12:32,676 --> 00:12:35,036
Speaker 1: And so so there's this search for a for a

213
00:12:35,076 --> 00:12:37,956
Speaker 1: new drug that is longer lasting, right, that you in

214
00:12:37,996 --> 00:12:40,796
Speaker 1: fact have found spoiler alert, But tell me about the

215
00:12:41,116 --> 00:12:41,956
Speaker 1: search for that drug.

216
00:12:42,636 --> 00:12:47,276
Speaker 2: The idea was that HIV has a structural element called

217
00:12:47,356 --> 00:12:50,156
Speaker 2: it's capsid, where it encloses the nucleic acid of the

218
00:12:50,196 --> 00:12:52,236
Speaker 2: virus within the virus.

219
00:12:52,076 --> 00:12:54,436
Speaker 1: It's it's like it's the bag, right, It's the protein.

220
00:12:54,636 --> 00:12:58,556
Speaker 2: It's yeah, it's a protein coming. It's like a yeah.

221
00:12:58,356 --> 00:13:00,476
Speaker 2: And I always want to think it's stronger than the bag.

222
00:13:00,636 --> 00:13:01,956
Speaker 2: It's stronger than a bag.

223
00:13:02,036 --> 00:13:06,836
Speaker 1: It's like okay, it like akayas case flask okay, okay.

224
00:13:07,396 --> 00:13:09,836
Speaker 2: And that's the virus is coming into the cell that

225
00:13:09,956 --> 00:13:11,876
Speaker 2: opens and dumps the new class ass and out. So

226
00:13:11,916 --> 00:13:14,156
Speaker 2: the virus is infecting and when it leaves it encapsulates

227
00:13:14,156 --> 00:13:18,036
Speaker 2: the begin and floats away. And targeting that is particularly hard,

228
00:13:18,036 --> 00:13:21,716
Speaker 2: and the work on it began a dozen years before

229
00:13:22,196 --> 00:13:25,236
Speaker 2: took a dozen years from the work to start before

230
00:13:25,276 --> 00:13:27,316
Speaker 2: we've even tested any human being for the first time,

231
00:13:28,796 --> 00:13:34,236
Speaker 2: and four thousand molecules were synthesized and screened in test

232
00:13:34,236 --> 00:13:35,996
Speaker 2: tubes and animals, selling them other things to be able

233
00:13:36,036 --> 00:13:38,636
Speaker 2: to be able to bring forward one to be able

234
00:13:38,676 --> 00:13:41,116
Speaker 2: to test in human beings, which then became a lot

235
00:13:41,116 --> 00:13:41,556
Speaker 2: of capeer.

236
00:13:45,596 --> 00:13:46,916
Speaker 1: We'll be back in a minute.

237
00:13:56,796 --> 00:13:59,876
Speaker 2: A virus like HIV has a certain number of proteins

238
00:13:59,876 --> 00:14:03,116
Speaker 2: that make it function right and caps it had not

239
00:14:03,196 --> 00:14:06,036
Speaker 2: been targeted and as a result of a great question

240
00:14:06,076 --> 00:14:08,036
Speaker 2: to say, could we target this part of the virus

241
00:14:08,036 --> 00:14:10,956
Speaker 2: in a way that it's different. This is important for

242
00:14:11,116 --> 00:14:16,356
Speaker 2: HIV broadly because what has been the success of treating

243
00:14:16,436 --> 00:14:19,476
Speaker 2: HIV is being able to target the virus in multiple places,

244
00:14:20,676 --> 00:14:24,396
Speaker 2: in multiple components of its life cycle, and that is

245
00:14:24,476 --> 00:14:28,796
Speaker 2: what makes up a treatment cocktail for HIV. Multiple medications

246
00:14:29,316 --> 00:14:32,036
Speaker 2: usually the target different parts of the virus life cycle

247
00:14:32,116 --> 00:14:34,996
Speaker 2: at the same time, and from a safety point of view,

248
00:14:35,036 --> 00:14:38,076
Speaker 2: actually ones that are very specific to the virus itself

249
00:14:38,236 --> 00:14:43,756
Speaker 2: and don't have effects on us. And so a enzyme

250
00:14:43,796 --> 00:14:46,236
Speaker 2: that only the virus makes, or in this case, protein

251
00:14:46,276 --> 00:14:48,756
Speaker 2: protein interaction that only the virus has, is a great

252
00:14:48,996 --> 00:14:53,996
Speaker 2: target because there's nothing that looks like that in our

253
00:14:54,396 --> 00:14:55,276
Speaker 2: regular systems.

254
00:14:56,116 --> 00:14:58,836
Speaker 1: So basically that means people are likely to have fewer

255
00:14:58,876 --> 00:15:01,636
Speaker 1: side effects because our own cells aren't gonna be bothered.

256
00:15:02,076 --> 00:15:04,476
Speaker 1: So it seems like a promising target because it's this

257
00:15:04,556 --> 00:15:06,836
Speaker 1: weird thing that the virus does that we don't do.

258
00:15:07,596 --> 00:15:11,356
Speaker 1: And then drug researchers find this, this molecule, right, this

259
00:15:11,556 --> 00:15:14,756
Speaker 1: potential drug that will eventually be called len.

260
00:15:14,596 --> 00:15:15,276
Speaker 2: A cap of bear.

261
00:15:15,956 --> 00:15:18,796
Speaker 1: But but there's what seems like a problem with this

262
00:15:18,916 --> 00:15:21,556
Speaker 1: with this molecule, right, and the problem is that it's

263
00:15:21,636 --> 00:15:25,716
Speaker 1: not very soluble in water. It doesn't dissolve well in water.

264
00:15:26,196 --> 00:15:27,716
Speaker 1: Tell tell me about that part of it.

265
00:15:28,756 --> 00:15:31,796
Speaker 2: There people who work on it. Just sometimes you do

266
00:15:31,796 --> 00:15:33,436
Speaker 2: a lot of work to try to figure out the

267
00:15:33,476 --> 00:15:36,756
Speaker 2: best what's got the best attack on the virus itself

268
00:15:36,756 --> 00:15:38,876
Speaker 2: around the end time you're trying to target itself. And

269
00:15:38,916 --> 00:15:42,636
Speaker 2: then it's not particularly soluble problem because that like medicines

270
00:15:42,636 --> 00:15:45,996
Speaker 2: that we take through our mouth, for example, like most

271
00:15:45,996 --> 00:15:49,796
Speaker 2: medicine surge IVY need to dissolve an order for us

272
00:15:49,836 --> 00:15:52,436
Speaker 2: to absorb them. And actually a lot of work goes

273
00:15:52,476 --> 00:15:55,276
Speaker 2: into one one's doing drug development, and maybe you figure

274
00:15:55,276 --> 00:15:56,796
Speaker 2: out the thing that targets best, and then you figure

275
00:15:56,796 --> 00:15:58,756
Speaker 2: out how to modify it ever as best you can

276
00:15:59,196 --> 00:16:01,316
Speaker 2: to be able to absorb it, because if you can't

277
00:16:01,316 --> 00:16:02,996
Speaker 2: absorb it doesn't have an effect.

278
00:16:02,916 --> 00:16:05,516
Speaker 1: Right you want you want it to dissolve in water.

279
00:16:05,556 --> 00:16:07,716
Speaker 1: You want to take it and then it dissolves and

280
00:16:08,276 --> 00:16:10,956
Speaker 1: goes off into your correct exactly.

281
00:16:11,716 --> 00:16:16,116
Speaker 2: It's the tremendous advantage of Lena kaeper beer has been

282
00:16:16,556 --> 00:16:21,276
Speaker 2: for what it eventually became is that when it's formulated

283
00:16:21,276 --> 00:16:25,356
Speaker 2: as an injection, it forms a deepot of the drug,

284
00:16:25,476 --> 00:16:28,916
Speaker 2: well deposit of the drug that dissolves slowly over time

285
00:16:28,956 --> 00:16:31,236
Speaker 2: because it isn't immediately soluble.

286
00:16:31,316 --> 00:16:34,276
Speaker 1: And like, was there a moment when somebody sort of

287
00:16:34,356 --> 00:16:37,756
Speaker 1: just realized like, oh, this this bug could actually be

288
00:16:37,956 --> 00:16:40,236
Speaker 1: you know, like an amazing feature. You know the fact

289
00:16:40,276 --> 00:16:42,636
Speaker 1: that it's not soluble, like it might mean we could

290
00:16:42,676 --> 00:16:44,596
Speaker 1: give this drug to people and it would last a

291
00:16:44,636 --> 00:16:45,556
Speaker 1: really long time.

292
00:16:46,116 --> 00:16:47,996
Speaker 2: I don't think that there's an exact moment. I think

293
00:16:47,996 --> 00:16:51,476
Speaker 2: there's actually many moments along the way or a discovery

294
00:16:51,596 --> 00:16:54,516
Speaker 2: like this, it's what do we have? How do we

295
00:16:54,556 --> 00:16:56,716
Speaker 2: improve on that? Where could we get to? And I

296
00:16:56,716 --> 00:16:59,676
Speaker 2: think the I will tell you the very first testing

297
00:16:59,716 --> 00:17:01,876
Speaker 2: of lena caprier was not a six month injection.

298
00:17:02,516 --> 00:17:04,756
Speaker 1: So over time, a lot of whiteboards, a lot of

299
00:17:04,796 --> 00:17:07,956
Speaker 1: rooms full of people, you get to this idea of oh,

300
00:17:07,996 --> 00:17:10,436
Speaker 1: we could do this as an injection that lasts four

301
00:17:10,436 --> 00:17:11,236
Speaker 1: months and months.

302
00:17:11,516 --> 00:17:11,636
Speaker 3: Right.

303
00:17:11,956 --> 00:17:12,156
Speaker 2: Yeah.

304
00:17:12,396 --> 00:17:16,276
Speaker 1: So there's two big sort of pivotal trials that you run, right,

305
00:17:16,276 --> 00:17:17,036
Speaker 1: tell me about them.

306
00:17:17,316 --> 00:17:20,716
Speaker 2: It's actually an entire program called Purpose And there are

307
00:17:20,756 --> 00:17:22,516
Speaker 2: two trials, Purpose one in Purpose two.

308
00:17:23,156 --> 00:17:25,316
Speaker 1: What's the acronym you say, Purpose? I got to ask

309
00:17:25,356 --> 00:17:25,996
Speaker 1: you for the acronym.

310
00:17:26,076 --> 00:17:29,916
Speaker 2: Oh, no, so the actually that acronym really is really complicated.

311
00:17:31,036 --> 00:17:36,636
Speaker 2: It is not a clear pee you are, so, yeah, no, yeah,

312
00:17:36,636 --> 00:17:39,636
Speaker 2: I don't make these up. But the trials are run

313
00:17:39,676 --> 00:17:44,796
Speaker 2: across five continents, thousands of people, almost ten thousand people

314
00:17:44,796 --> 00:17:47,956
Speaker 2: in total. And the two trials Purpose one and two

315
00:17:48,756 --> 00:17:53,596
Speaker 2: were the trials that specifically are phase three pivotal trials

316
00:17:53,596 --> 00:17:55,596
Speaker 2: for testing whether something is safe and effective.

317
00:17:56,956 --> 00:17:57,876
Speaker 1: And what were the results?

318
00:17:58,836 --> 00:18:03,196
Speaker 2: Yeah, so Purpose one is among Allison girls and young

319
00:18:03,236 --> 00:18:08,156
Speaker 2: women in South Africa Uganda. It's almost five thousand people

320
00:18:08,196 --> 00:18:11,156
Speaker 2: in the trial who were either taking the daily pill

321
00:18:11,316 --> 00:18:14,196
Speaker 2: or taking the injection. And the among people who were

322
00:18:14,236 --> 00:18:17,476
Speaker 2: assigned the injection, zero infections occurred for the primary d

323
00:18:17,516 --> 00:18:19,876
Speaker 2: priant of the trial, which had never been seen before

324
00:18:19,916 --> 00:18:21,236
Speaker 2: for an HIV prevention trial.

325
00:18:21,756 --> 00:18:26,036
Speaker 1: So okay, so zero absolutely no. One of the two

326
00:18:26,116 --> 00:18:29,716
Speaker 1: thousand or so people who got lenni kapavir, none of

327
00:18:29,756 --> 00:18:32,556
Speaker 1: them got HIV in the control group. So they were

328
00:18:32,556 --> 00:18:36,956
Speaker 1: taking in the control group of the anti retroviral pills

329
00:18:36,996 --> 00:18:40,596
Speaker 1: that are standard. Now, how many of those people got HIV.

330
00:18:40,916 --> 00:18:44,276
Speaker 2: For people who are getting the control pill, which is

331
00:18:44,516 --> 00:18:48,876
Speaker 2: active prep, the approved active crap, sixteen out of about

332
00:18:48,916 --> 00:18:49,916
Speaker 2: one thousand.

333
00:18:51,076 --> 00:18:53,036
Speaker 1: So sixteen out of a thousand is kind of a lot.

334
00:18:53,196 --> 00:18:54,876
Speaker 1: This is like over the course of what a year.

335
00:18:54,916 --> 00:18:58,996
Speaker 2: Or something about a year a year follow and in

336
00:18:59,116 --> 00:19:02,956
Speaker 2: almost all the cases of the sixteen it's because invested

337
00:19:03,036 --> 00:19:06,756
Speaker 2: blood samples from those individuals they weren't using it, and

338
00:19:07,476 --> 00:19:11,196
Speaker 2: a testament to for some people how challenging it can

339
00:19:11,276 --> 00:19:15,316
Speaker 2: be to use something every day and how something that

340
00:19:15,756 --> 00:19:19,676
Speaker 2: injection twice a year for many people both could be

341
00:19:19,716 --> 00:19:23,396
Speaker 2: very effective, but also is something that they can make

342
00:19:23,436 --> 00:19:26,796
Speaker 2: workable because you can set it and not think about.

343
00:19:26,556 --> 00:19:31,916
Speaker 1: It, Okay, forget it. What's the other What was the

344
00:19:31,956 --> 00:19:33,796
Speaker 1: result of the second pivotal trial.

345
00:19:34,196 --> 00:19:37,996
Speaker 2: Yeah, the second pivotal trial was the more geographically diverse

346
00:19:38,556 --> 00:19:41,796
Speaker 2: group and was men, transgender women, and men and gender

347
00:19:41,836 --> 00:19:45,716
Speaker 2: non binary people in Asia, North and South America and Africa.

348
00:19:45,716 --> 00:19:50,116
Speaker 2: It's really broad and global. Yes, And in that study,

349
00:19:50,276 --> 00:19:52,796
Speaker 2: again among about two thousand people, there were only two

350
00:19:52,836 --> 00:19:58,676
Speaker 2: infections that occurred compared to nine infections among about a

351
00:19:58,676 --> 00:20:02,916
Speaker 2: thousand people who received the control so also quite a difference.

352
00:20:03,476 --> 00:20:07,076
Speaker 1: Yes, I mean, presumably the larger audience or the larger

353
00:20:07,196 --> 00:20:09,676
Speaker 1: patient population is the people who aren't taking oral prep

354
00:20:09,716 --> 00:20:13,316
Speaker 1: at all. Precisely, and you can't randomize ethically to that.

355
00:20:13,516 --> 00:20:15,076
Speaker 1: You can't have a control group where it's like we're

356
00:20:15,076 --> 00:20:16,556
Speaker 1: not going to give them anything and we're going to

357
00:20:16,556 --> 00:20:18,756
Speaker 1: see how they do. But in real life, that is

358
00:20:19,196 --> 00:20:21,876
Speaker 1: probably the population you're looking for.

359
00:20:21,796 --> 00:20:22,476
Speaker 2: Right exactly.

360
00:20:22,516 --> 00:20:26,756
Speaker 1: So okay, congratulations on the successful outcome of the trials.

361
00:20:27,076 --> 00:20:27,796
Speaker 1: Where are you now?

362
00:20:29,236 --> 00:20:32,716
Speaker 2: Oh so you know, bigger mind we talked about before.

363
00:20:32,796 --> 00:20:35,756
Speaker 2: You know, just because science can be the science may

364
00:20:35,796 --> 00:20:39,476
Speaker 2: be fantastic, you may have a great publication or a

365
00:20:39,516 --> 00:20:41,836
Speaker 2: great p value for science, it doesn't mean that people

366
00:20:41,876 --> 00:20:44,476
Speaker 2: actually get medicine. And so the medicine when the cover

367
00:20:44,556 --> 00:20:48,796
Speaker 2: has been submitted to regulatory agencies, because drug approvals.

368
00:20:48,276 --> 00:20:52,076
Speaker 4: Are a necessary step for people to receive them, and

369
00:20:52,116 --> 00:20:57,636
Speaker 4: that rigorous process is ongoing now and regulatory parentcies all

370
00:20:57,676 --> 00:20:58,356
Speaker 4: around the world.

371
00:20:58,436 --> 00:21:01,796
Speaker 2: From the beginning, the thought has been for loutic cover

372
00:21:01,876 --> 00:21:04,676
Speaker 2: that's a medicine that can have a global impact, and

373
00:21:05,156 --> 00:21:10,236
Speaker 2: then readying for being able to make it and distribute

374
00:21:10,236 --> 00:21:12,916
Speaker 2: it for people all around the world. As we have

375
00:21:12,956 --> 00:21:15,396
Speaker 2: been doing all of those steps, the dissemination of the science,

376
00:21:15,836 --> 00:21:21,116
Speaker 2: the regulatory submissions, we've been simultaneously making plans for global

377
00:21:21,156 --> 00:21:23,996
Speaker 2: access particularly access for low and lower middle income countries,

378
00:21:24,036 --> 00:21:26,276
Speaker 2: and that part of the story is as important as

379
00:21:26,316 --> 00:21:30,996
Speaker 2: everything else because success for ending HIV is it has

380
00:21:31,036 --> 00:21:32,116
Speaker 2: to be a global success.

381
00:21:32,836 --> 00:21:35,236
Speaker 1: Yeah, so let's talk about that. I mean, there's obviously

382
00:21:35,836 --> 00:21:41,436
Speaker 1: an interesting history of getting HIV drugs to lower income

383
00:21:41,556 --> 00:21:44,476
Speaker 1: countries that largely has been a success. Right, people don't

384
00:21:44,476 --> 00:21:47,356
Speaker 1: talk about it that much anymore, but it's a good,

385
00:21:47,556 --> 00:21:52,556
Speaker 1: happy story. Ultimately, what's happening with Lena kapavir that in

386
00:21:52,596 --> 00:21:54,876
Speaker 1: that context, Yes, the the.

387
00:21:55,676 --> 00:21:57,716
Speaker 2: You know, we talked back about my earlier history and

388
00:21:57,756 --> 00:22:00,476
Speaker 2: I remember well when there were no medicines in lower

389
00:22:00,516 --> 00:22:03,876
Speaker 2: middle income countries and then when there was, and that

390
00:22:04,476 --> 00:22:07,356
Speaker 2: was a delay of years and years. And that's not

391
00:22:07,476 --> 00:22:10,956
Speaker 2: unique to HIV. That is for innovations and health in general,

392
00:22:10,956 --> 00:22:14,156
Speaker 2: that it can take years or decades for medicines to

393
00:22:14,236 --> 00:22:19,516
Speaker 2: make it from when they're discovered to even approval and

394
00:22:19,556 --> 00:22:26,676
Speaker 2: then availability in low income countries. For lenikapavier years ahead

395
00:22:26,716 --> 00:22:29,796
Speaker 2: of results, truly years ahead before we had results. We

396
00:22:29,796 --> 00:22:34,876
Speaker 2: were thinking about how we can compress that calendar, and

397
00:22:35,316 --> 00:22:40,316
Speaker 2: that included within weeks of the Purpose trials reading out

398
00:22:40,716 --> 00:22:44,556
Speaker 2: an announcement that we'd signed voluntary license agreements which are

399
00:22:44,676 --> 00:22:47,516
Speaker 2: which allow a generic manufacturer to make a version of

400
00:22:47,556 --> 00:22:50,836
Speaker 2: the medicine. So would volntarize de agreees with six generic

401
00:22:50,876 --> 00:22:56,356
Speaker 2: manufacturers covering one hundred and twenty countries low and lower

402
00:22:56,396 --> 00:22:59,516
Speaker 2: mediome countries to be able to make generic versions in

403
00:22:59,556 --> 00:23:02,956
Speaker 2: the medicines royalty free and no profit real that as

404
00:23:02,956 --> 00:23:05,716
Speaker 2: soon as they're able to, so as soon as they

405
00:23:05,876 --> 00:23:08,956
Speaker 2: can ramp up their technical capacity to be able to

406
00:23:08,956 --> 00:23:10,956
Speaker 2: make these medicines.

407
00:23:10,836 --> 00:23:13,916
Speaker 1: So it will be cheap for people in four parts

408
00:23:13,956 --> 00:23:16,276
Speaker 1: of the world. And what does that mean sub Saharan Africa,

409
00:23:16,476 --> 00:23:20,116
Speaker 1: parts of Asia exactly? What about well, what's it going

410
00:23:20,156 --> 00:23:22,356
Speaker 1: to cost in the US? And how does how does

411
00:23:22,396 --> 00:23:25,716
Speaker 1: like insurance work for PREP? Insurance cover PREP.

412
00:23:25,756 --> 00:23:28,596
Speaker 2: So insurance dots cover PREP in the United States. And

413
00:23:28,956 --> 00:23:34,156
Speaker 2: the CDC has done really extensive analysis yes, to summarize

414
00:23:34,196 --> 00:23:36,556
Speaker 2: a lot of really good signs there their conclusions that

415
00:23:36,796 --> 00:23:40,516
Speaker 2: access to PREP is not limited by insurance coverage, that

416
00:23:40,516 --> 00:23:42,756
Speaker 2: there are two thirds of people who could most benefit

417
00:23:43,076 --> 00:23:45,516
Speaker 2: using PREP. That's not for insurance reasons, that is for

418
00:23:45,876 --> 00:23:47,756
Speaker 2: all kinds of the other reasons that we talked about

419
00:23:47,916 --> 00:23:49,876
Speaker 2: of stigma and and I think that's a strategy looking

420
00:23:49,876 --> 00:23:52,396
Speaker 2: forward to to len ACAFA. It's not proved yet United States,

421
00:23:52,436 --> 00:23:55,996
Speaker 2: so there's not both insurance coverage and other things are

422
00:23:56,036 --> 00:23:59,836
Speaker 2: not said yet. Those don't happen until the FDA is

423
00:23:59,876 --> 00:24:03,036
Speaker 2: able to do their rigorous assessment about the efficating and

424
00:24:03,076 --> 00:24:03,996
Speaker 2: safety of the medicine.

425
00:24:04,556 --> 00:24:07,596
Speaker 1: So, Okay, you've been working on HIV for for a

426
00:24:07,596 --> 00:24:10,676
Speaker 1: long time now, right for deaths, And I'm curious when

427
00:24:10,716 --> 00:24:13,756
Speaker 1: you sort of take the long view and you step back,

428
00:24:14,516 --> 00:24:15,116
Speaker 1: what do you see?

429
00:24:15,996 --> 00:24:18,316
Speaker 2: Oh, you know, I have been doing this for a

430
00:24:18,356 --> 00:24:23,276
Speaker 2: long time, and what has always motivated me is you

431
00:24:23,316 --> 00:24:25,716
Speaker 2: know it is actually ending the epidemic.

432
00:24:25,756 --> 00:24:28,556
Speaker 1: When you say ending the epidemic, I mean like I

433
00:24:28,596 --> 00:24:32,116
Speaker 1: think of a vaccine and a global eradication campaign. Is

434
00:24:32,116 --> 00:24:33,716
Speaker 1: that what you mean when you say that.

435
00:24:34,396 --> 00:24:36,636
Speaker 2: I want to stop new infections. I want to be

436
00:24:36,636 --> 00:24:38,396
Speaker 2: able to stop my infections as much as we can.

437
00:24:38,756 --> 00:24:42,476
Speaker 2: I want to have treatments that are availed to every

438
00:24:42,516 --> 00:24:44,676
Speaker 2: person living with HIV that allow them to live a

439
00:24:44,676 --> 00:24:47,436
Speaker 2: full life, and as a result, turning off the tap

440
00:24:47,476 --> 00:24:51,396
Speaker 2: of new infections, treating effectively the infections that are existing,

441
00:24:52,556 --> 00:24:58,916
Speaker 2: then the public health emergency diminishes, and the cloud that

442
00:24:59,036 --> 00:25:00,196
Speaker 2: is ACHIV on the world.

443
00:25:04,476 --> 00:25:06,436
Speaker 1: We'll be back in a minute with the lighting round.

444
00:25:16,076 --> 00:25:19,716
Speaker 1: You have undergraduate degrees, as I understand it, in both

445
00:25:19,796 --> 00:25:24,356
Speaker 1: biochemistry and comparative religion. Which religions did you compare in

446
00:25:24,396 --> 00:25:24,996
Speaker 1: which one.

447
00:25:24,836 --> 00:25:27,476
Speaker 2: One one one?

448
00:25:28,276 --> 00:25:29,116
Speaker 1: Which one lost?

449
00:25:30,716 --> 00:25:33,316
Speaker 2: Now I have an undergraduator in comparative religion, which I love.

450
00:25:33,476 --> 00:25:37,156
Speaker 2: I love the interface of society and health, society and

451
00:25:37,796 --> 00:25:40,956
Speaker 2: person of religion. Degree was a great way to get out.

452
00:25:41,796 --> 00:25:44,076
Speaker 1: I mean, tell me one thing, like what were you

453
00:25:44,156 --> 00:25:45,076
Speaker 1: actually interested in?

454
00:25:45,156 --> 00:25:45,676
Speaker 2: What? What? Like?

455
00:25:45,716 --> 00:25:48,756
Speaker 1: What like? Tell me one thing you learned in studying

456
00:25:48,796 --> 00:25:49,556
Speaker 1: comparative religion.

457
00:25:50,716 --> 00:25:55,236
Speaker 2: Oh, I don't many things in comparive religion. I loved.

458
00:25:55,716 --> 00:25:58,796
Speaker 2: I love complicated religious texts on how societies have fought

459
00:25:58,836 --> 00:26:02,596
Speaker 2: through mystery in the world. I loved American religions because

460
00:26:02,676 --> 00:26:05,076
Speaker 2: there's so much variety in the United States and it

461
00:26:05,116 --> 00:26:08,796
Speaker 2: reflects a lot of the energy of the US for

462
00:26:08,876 --> 00:26:13,476
Speaker 2: you know, all different directions. I have dynamism of dynamism

463
00:26:13,676 --> 00:26:17,116
Speaker 2: of religion, and what religion says about society like still

464
00:26:17,116 --> 00:26:19,876
Speaker 2: influences my all of the stuff I do.

465
00:26:19,916 --> 00:26:23,516
Speaker 1: Now, what's your second least favorite virus?

466
00:26:24,516 --> 00:26:26,236
Speaker 2: Second least favorite virus?

467
00:26:26,676 --> 00:26:28,756
Speaker 1: I'm assuming HIV is your least favorite.

468
00:26:29,116 --> 00:26:32,076
Speaker 2: HIV is my well, HIV is my favorite book favorite.

469
00:26:32,756 --> 00:26:35,356
Speaker 1: There's two ways to frame it, right, favorite or least favorite,

470
00:26:35,436 --> 00:26:37,356
Speaker 1: kind of the same. What's the number two after HIV?

471
00:26:38,396 --> 00:26:38,636
Speaker 3: Oh?

472
00:26:39,396 --> 00:26:42,276
Speaker 2: Hmm? Flu? Like which one is? I want to like

473
00:26:42,356 --> 00:26:44,996
Speaker 2: white from the world. Flu would be great, big impact,

474
00:26:46,956 --> 00:26:52,876
Speaker 2: terrible viruses that would be like a Goola Marburg that

475
00:26:52,916 --> 00:26:56,276
Speaker 2: we'd love to that I'd love to see remove the world.

476
00:26:56,436 --> 00:27:00,036
Speaker 2: All the viral epatitis viruses there's multiples of them that

477
00:27:00,196 --> 00:27:03,516
Speaker 2: have tremendous prevalence in the world and don't get as

478
00:27:03,596 --> 00:27:07,836
Speaker 2: much attention but kill lots of people. Would be great

479
00:27:07,836 --> 00:27:08,356
Speaker 2: to eradic it.

480
00:27:09,516 --> 00:27:12,516
Speaker 1: How many papers have you co authored that quote, Tina Turner?

481
00:27:13,716 --> 00:27:18,156
Speaker 2: Oh, the quote one, Yes, there's one. There's there's one

482
00:27:18,156 --> 00:27:19,876
Speaker 2: with a what's love got to do with the title? Yes?

483
00:27:19,876 --> 00:27:21,796
Speaker 2: Which is about it was about like the motivations to

484
00:27:21,876 --> 00:27:24,156
Speaker 2: take prep right, the motivations to take prep are not

485
00:27:24,876 --> 00:27:27,676
Speaker 2: simply because someone waged their finger at you and said

486
00:27:27,676 --> 00:27:29,396
Speaker 2: take your medicine. Yeah. Love.

487
00:27:36,276 --> 00:27:41,036
Speaker 1: Jared Baton is senior vice president in virology at Kilead Sciences.

488
00:27:42,236 --> 00:27:44,236
Speaker 1: Just a quick note, we'll be off for the next

489
00:27:44,236 --> 00:27:46,356
Speaker 1: few weeks on a planned hiatus.

490
00:27:46,516 --> 00:27:47,316
Speaker 2: We'll be back soon.

491
00:27:47,996 --> 00:27:51,156
Speaker 1: Today's show was produced by Gabriel Hunter Chang, edited by

492
00:27:51,236 --> 00:27:55,396
Speaker 1: Lydia Jean Kott, and engineered by Sarah Buguer. I'm Jacob Goldstein.

493
00:27:55,596 --> 00:27:56,356
Speaker 2: Thanks for listening.